Fremanezumab, sold under the brand name Ajovy, is a migraine prevention drug that has now shown meaningful antidepressant effects in a rigorous clinical trial. The UNITE trial, published in JAMA Neurology in May 2025 and led by Dr. Richard B. Lipton of Albert Einstein College of Medicine, found that patients receiving monthly fremanezumab injections experienced both significantly fewer migraine days and statistically significant reductions in depression scores compared to placebo. This makes fremanezumab the first drug specifically studied in a randomized clinical trial for treating both migraine and comorbid major depressive disorder at the same time.
The connection between migraine and depression is not incidental. People with migraine are two to five times more likely to have depression than the general population, and roughly 30 to 50 percent of chronic migraine patients also carry a diagnosis of major depressive disorder. For years, neurologists and psychiatrists have used older medications like amitriptyline and venlafaxine to address both conditions, but these drugs come with side effect profiles that many patients find difficult to tolerate. The UNITE trial results suggest a newer, more targeted option may now be available. This article covers the UNITE trial findings in detail, how fremanezumab compares to traditional dual-purpose medications, what the results mean for patients managing both conditions, and what limitations and open questions remain.
Table of Contents
- How Does a Migraine Prevention Drug Also Treat Depression?
- The Chicken-and-Egg Problem With Pain and Depression
- How Fremanezumab Compares to Traditional Dual-Purpose Treatments
- What This Means for Patients Managing Both Migraine and Depression
- Limitations of the UNITE Trial and Unanswered Questions
- Why the Migraine-Depression Link Matters for Brain Health
- What Comes Next for Dual-Purpose Migraine and Depression Treatment
- Conclusion
- Frequently Asked Questions
How Does a Migraine Prevention Drug Also Treat Depression?
The UNITE trial enrolled 353 adult patients with a mean age of 43, of whom 88 percent were women. About half had episodic migraine and half had chronic migraine, and all had been living with comorbid major depressive disorder for at least 12 months. Patients were randomized to receive either 225 milligrams of fremanezumab per month or placebo, and the study ran from July 2020 through August 2022 in a double-blind, placebo-controlled design. The migraine results were striking on their own. Patients on fremanezumab saw an average reduction of 5.1 migraine days per month, compared to 2.9 days for those on placebo.
The 50 percent responder rate, meaning the proportion of patients who cut their monthly migraine days in half or more, was 33 percent in the fremanezumab group versus just 13 percent on placebo, a difference that was statistically significant at P less than .001. But the depression findings are what made the trial unusual. Patients on fremanezumab also showed statistically significant reductions in depression rating scales compared to placebo. Fremanezumab is a CGRP monoclonal antibody, a class of drug designed to block calcitonin gene-related peptide, a molecule heavily involved in migraine pathology. Whether the drug acts directly on depression through neurobiological pathways or indirectly by relieving the burden of chronic pain remains an open and important question.
The Chicken-and-Egg Problem With Pain and Depression
One of the most important caveats about the UNITE trial is the timing of improvement. Some researchers noted that reductions in migraine days appeared to precede the drop in depressive symptoms. this raises a reasonable concern: the antidepressant effect might be largely indirect. When someone goes from 15 debilitating migraine days per month to 10, their mood is likely to improve simply because they are in less pain, missing less work, and able to participate more fully in daily life. However, the indirect explanation does not tell the whole story. Preclinical data suggest that anti-CGRP drugs may have direct antidepressant properties.
CGRP receptors are found throughout brain regions involved in mood regulation, and animal studies have shown behavioral changes consistent with antidepressant effects when CGRP signaling is blocked. Researchers involved in the UNITE trial have described a direct antidepressant effect as “plausible” based on this evidence, though not yet proven in humans. For patients and clinicians, the practical distinction may matter less than the outcome. If a single monthly injection reduces both migraine frequency and depression severity, the mechanism is secondary to the relief. Still, anyone considering fremanezumab primarily for depression rather than migraine should understand that the drug is approved and indicated for migraine prevention, not depression. The antidepressant benefit, while real in this trial, has not been replicated independently, and no regulatory body has approved any CGRP inhibitor for the treatment of depression.
How Fremanezumab Compares to Traditional Dual-Purpose Treatments
Long before CGRP inhibitors existed, neurologists relied on older medications that happened to address both migraine and depression. Amitriptyline, a tricyclic antidepressant, has the most evidence among antidepressants for migraine prevention. At a dose of 25 milligrams, it can be effective for migraine alone, but when depression or neuropathic pain are also present, doses of 75 to 100 milligrams are typically needed. The trade-off is a familiar list of side effects: drowsiness, weight gain, dry mouth, constipation, and cardiac rhythm concerns at higher doses. SNRIs such as venlafaxine and duloxetine are considered among the most effective treatments for patients with co-occurring migraine and depression. They work by increasing both serotonin and norepinephrine, neurotransmitters involved in pain modulation and mood.
One randomized controlled trial found that combining amitriptyline with topiramate was superior to either drug alone, specifically in terms of depression scores, side effects, and patient satisfaction in migraine patients with comorbid depression. This combination approach, while effective, requires managing two medications with distinct side effect profiles. Fremanezumab offers a different profile entirely. As a monoclonal antibody given by injection once a month, it bypasses the gastrointestinal system and avoids many of the daily-pill side effects that lead patients to abandon oral preventives. The most common side effects are injection site reactions. For a patient who has tried amitriptyline and could not tolerate the sedation, or who found venlafaxine caused intolerable nausea, fremanezumab represents a genuinely different category of treatment.
What This Means for Patients Managing Both Migraine and Depression
The American Headache Society now considers CGRP inhibitors a first-line option for migraine prevention, a shift from their earlier position as second-line treatments to be tried only after older drugs had failed. This change in guidelines means that patients no longer need to cycle through amitriptyline, topiramate, or beta-blockers before their insurance will cover a CGRP inhibitor. For someone with both migraine and depression, this is a meaningful development. At least one researcher quoted in Medscape coverage of the UNITE trial stated that he now preferentially uses fremanezumab when treating migraine patients who also have depression. This does not mean fremanezumab should replace antidepressant therapy across the board.
A patient with severe major depressive disorder needs treatment directed at that condition, whether through SSRIs, SNRIs, psychotherapy, or a combination. But for the patient whose depression is moderate, intertwined with their migraine burden, and partially driven by chronic pain, fremanezumab might reduce the need for a separate antidepressant or at least make the overall treatment regimen simpler. The trade-off is cost. CGRP monoclonal antibodies are expensive, often running several hundred dollars per month even with insurance, and prior authorization requirements remain common. Amitriptyline, by contrast, costs a few dollars per month as a generic. Patients and their physicians need to weigh the tolerability and convenience advantages of fremanezumab against the reality that older, cheaper drugs also work for many people.
Limitations of the UNITE Trial and Unanswered Questions
The UNITE trial, while well-designed, had several limitations worth understanding. The study included 353 patients, a reasonable sample but modest compared to the large trials that established CGRP inhibitors for migraine prevention alone. The 12-week treatment period was relatively short for assessing antidepressant effects, as most depression treatments are evaluated over longer periods and many patients with MDD require months to achieve full remission. The patient population was also specific. Participants had both episodic or chronic migraine and comorbid major depressive disorder lasting at least 12 months.
It is unclear whether the depression benefits would extend to patients with milder depressive symptoms, treatment-resistant depression, or depression without comorbid migraine. Extrapolating from 353 patients with a particular clinical profile to the broader population of people with migraine and mood disorders requires caution. There is also the matter of what the trial did not measure. Long-term effects beyond 12 weeks, impact on suicidal ideation, interactions with concurrent antidepressant medications, and effects on cognitive function and quality of life all remain areas for future study. For patients with dementia or cognitive impairment who also experience migraine and depression, no data currently exist on how CGRP inhibitors perform in that population.
Why the Migraine-Depression Link Matters for Brain Health
The overlap between migraine and depression is not merely a coincidence of two common conditions. Both involve disruptions in serotonin signaling, shared genetic risk factors, and overlapping brain circuits. Chronic migraine in particular has been associated with structural brain changes visible on imaging, including white matter lesions and altered connectivity in pain-processing networks.
Depression carries its own set of neurobiological consequences, including hippocampal volume reduction and impaired neuroplasticity. For a brain health audience, this overlap matters because undertreated migraine and depression may each accelerate cognitive decline through independent and synergistic mechanisms. A treatment that addresses both conditions simultaneously could, in theory, reduce the cumulative neurological burden. This remains speculative, but it underscores why the UNITE trial results are relevant beyond headache medicine alone.
What Comes Next for Dual-Purpose Migraine and Depression Treatment
The UNITE trial is likely to prompt further research into CGRP inhibitors and mood disorders. Other drugs in the same class, including erenumab, galcanezumab, and eptinezumab, have not been formally tested in randomized trials for comorbid depression, though anecdotal reports and post-hoc analyses have hinted at similar mood benefits. Larger, longer trials with depression as a primary rather than co-primary endpoint would help clarify whether the antidepressant effect is robust, durable, and independent of migraine improvement.
In the meantime, the practical takeaway is straightforward. If you or someone you care for lives with both migraine and depression, the treatment landscape has expanded. A conversation with a neurologist or headache specialist about CGRP inhibitors, and specifically about fremanezumab, is worth having. The older medications still work and remain appropriate for many patients, but they are no longer the only starting point.
Conclusion
The UNITE trial represents a genuine advance in how we think about treating migraine and depression together. Fremanezumab reduced migraine days by an average of 5.1 per month compared to 2.9 for placebo, and it produced statistically significant improvements in depression scores. Whether the antidepressant effect is direct, indirect through pain relief, or some combination of both, the clinical outcome is the same: patients felt better on multiple fronts.
For anyone navigating the intersection of chronic migraine and depression, the key next step is an honest conversation with a healthcare provider about the full range of options. Traditional medications like amitriptyline and venlafaxine remain effective and affordable. CGRP inhibitors like fremanezumab offer a newer mechanism with a different side effect profile and, now, evidence of mood benefits. The right choice depends on individual circumstances, treatment history, insurance coverage, and which symptoms are most disabling.
Frequently Asked Questions
Is fremanezumab approved by the FDA to treat depression?
No. Fremanezumab (Ajovy) is FDA-approved only for the prevention of migraine in adults. The UNITE trial showed antidepressant benefits, but no regulatory body has approved any CGRP inhibitor for treating depression. Any use for depression would be considered off-label.
Can I stop my antidepressant if I start fremanezumab for migraines?
You should not stop any antidepressant without direct guidance from your prescribing physician. The UNITE trial studied fremanezumab’s effects on depression, but it was not designed to test whether it could replace standard antidepressant therapy. Abruptly stopping antidepressants can cause withdrawal symptoms and relapse.
How quickly did depression improve in the UNITE trial?
The trial observed that migraine improvement tended to precede improvements in depressive symptoms. The study lasted 12 weeks, and statistically significant depression improvements were noted over this period, but the full timeline of response has not been characterized in detail.
Are other CGRP inhibitors also effective for depression?
The UNITE trial only studied fremanezumab. Other CGRP inhibitors such as erenumab, galcanezumab, and eptinezumab have not been formally tested in randomized trials for comorbid depression, though some anecdotal reports and post-hoc analyses have suggested possible mood benefits.
What are the main side effects of fremanezumab?
The most common side effects are injection site reactions, including redness, pain, or swelling at the injection site. Unlike older migraine preventives such as amitriptyline or topiramate, fremanezumab does not typically cause sedation, weight gain, or cognitive dulling.
Is fremanezumab appropriate for older adults or people with cognitive decline?
There are currently no published data on the use of CGRP inhibitors specifically in populations with dementia or significant cognitive impairment. Older adults with migraine and depression should discuss the risks and benefits with their neurologist, as clinical trial populations have been predominantly middle-aged.
